Oculis Holding AG (OCS) Non Operating Income (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Non Operating Income came in at -$9.2 million in Q1 2026, up 37.34% year-on-year from -$6.7 million in Q1 2025, and down 140.65% quarter-over-quarter from -$3.8 million in Q4 2025.
Oculis Holding AG (OCS) Non Operating Income (2022 - 2026) Analysis & Trends
Oculis Holding AG's Non Operating Income history runs 5 years deep, the most recent figure standing at -$9.2 million for Q1 2026.
- On a quarterly basis, Non Operating Income rose 37.34% year-over-year to -$9.2 million in Q1 2026; TTM through Mar 2026 was $6.9 billion, a 387.62% increase from a year earlier, with the FY2025 full-year figure at -$21.1 million, down 45.59% from the prior year.
- Non Operating Income eased to -$9.2 million in Q1 2026 per OCS's latest filing, from -$3.8 million in the prior quarter.
- Across five years, Non Operating Income topped out at $6.9 billion in Q3 2025 and bottomed at -$2.4 billion in Q3 2024.
- The 5-year median for Non Operating Income is -$3.5 million (2022), against an average of $278.1 million.
- Across the five-year window, Non Operating Income tumbled 45430.84% in 2024 and soared 391.6% in 2025, its largest moves.
- Year by year, Non Operating Income stood at -$5.6 million in 2022, then surged by 93.45% to -$369772.3 in 2023, then slumped by 3491.22% to -$13.3 million in 2024, then jumped by 71.14% to -$3.8 million in 2025, then slumped by 140.65% to -$9.2 million in 2026.
- Per Business Quant, the three latest OCS Non Operating Income figures stand at -$9.2 million (Q1 2026), -$3.8 million (Q4 2025), and $6.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | -46.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.22 Mn |
| Dec 31, 2025 | -3.83 Mn |
| Sep 30, 2025 | 6.87 Bn |
| Jun 30, 2025 | -5.59 Mn |
| Mar 31, 2025 | -14.72 Mn |
| Dec 31, 2024 | -13.28 Mn |
| Sep 30, 2024 | -2.36 Bn |
| Jun 30, 2024 | 1.85 Mn |
| Mar 31, 2024 | -1.90 Mn |
| Dec 31, 2023 | -369,772.27 |
| Sep 30, 2023 | -5.17 Mn |
| Jun 30, 2023 | -2.24 Mn |
| Mar 31, 2023 | 2.19 Mn |
| Dec 31, 2022 | -5.65 Mn |
| Sep 30, 2022 | -3.18 Mn |
| Jun 30, 2022 | -3.18 Mn |